BI
BIOT.SW L&G Pharma Breakthrough UCITS ETF USD Accumulating ETF
- CHF
No recent price
- Total assets
- 24.9M
- Expense ratio
- 0.50%
- Dividend yield
- -
- 1-year return
- +20.60%
- Holdings
- 10
- Since
- 2018
Fund data as reported by the issuer, updated Oct 30, 2026. Total assets are in the fund's base currency.
What does BIOT.SW invest in?
Tracks Morningstar Gbl Biotechnology NR USD- Mostly US stocks (67.9%)
- Largest sector: Healthcare (93.2%)
- Largest region: North America (67.6%)
- Top 3 holdings: 9.0% of the fund
Asset allocation
- US stocks 67.9%
- Non-US stocks 29.5%
- Cash 0.2%
Top holdings
- Xeris Pharmaceuticals Inc 3.16%
- United Therapeutics Corporation 3.01%
- Genmab A/S 2.84%
- Rigel Pharmaceuticals Inc 2.73%
- Recordati Industria Chimica e Farmaceutica S.p.A. 2.73%
L&G Pharma Breakthrough UCITS ETF USD Accumulating ETF performance
Sharpe ratio 0.42- This year
- +15.96%
- 1 year
- +20.60%
- 3 years
- +13.52%
- 5 years
- +1.30%
Volatility 17.5% over 1 year and 15.6% over 3 years. Moderate, similar to a broad stock index.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
BIOT.SW price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
L&G Pharma Breakthrough UCITS ETF USD Accumulating ETF top holdings
27.6% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Xeris Pharmaceuticals Inc XERS.US | Healthcare | United States | 3.16% |
| United Therapeutics Corporation UTHR.US | Healthcare | United States | 3.01% |
| Genmab A/S GMAB.CO | Healthcare | Denmark | 2.84% |
| Rigel Pharmaceuticals Inc RIGL.US | Healthcare | United States | 2.73% |
| Recordati Industria Chimica e Farmaceutica S.p.A. REC.MI | Healthcare | Italy | 2.73% |
| Basilea Pharmaceutica AG BSLN.SW | Healthcare | Switzerland | 2.71% |
| LG Chemicals 051910.KQ | - | Korea | 2.69% |
| Ligand Pharmaceuticals Incorporated LGND.US | Healthcare | United States | 2.66% |
| Biogen Inc BIIB.US | Healthcare | United States | 2.55% |
| Halozyme Therapeutics Inc HALO.US | Healthcare | United States | 2.53% |
BIOT.SW sector exposure
- Healthcare93.2%
- Basic Materials2.2%
Share of the stocks in the fund.
BIOT.SW regional exposure
- North America67.6%
- Europe Developed15.2%
- Japan9.0%
- Asia Developed2.5%
- Asia Emerging2.4%
Share of the stocks in the fund.
Company size
Average market cap 8.24B- Mega cap5.2%
- Big cap14.1%
- Medium cap32.8%
- Small cap29.1%
- Micro cap21.3%
L&G Pharma Breakthrough UCITS ETF USD Accumulating ETF fund profile
- Fund name
- L&G Pharma Breakthrough UCITS ETF USD Accumulating ETF
- Ticker
- BIOT.SW
- Exchange
- SIX Swiss Exchange
- Issuer
- LGIM Managers (Europe) Limited
- Index tracked
- Morningstar Gbl Biotechnology NR USD
- Category
- Healthcare Equity
- Inception date
- Jan 18, 2018
- Trading currency
- CHF
- Expense ratio
- 0.50%